Jointly provided by A. Webb Roberts Center for CME of Baylor Scott & White Health and CancerNet
Supported by Eisai, Inc.
This webcast is intended to improve care of patients with renal cell carcinoma by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This webcast is designed to meet the educational needs of hematologists/oncologists and other healthcare professionals who diagnose, treat, and manage patients with renal cell carcinoma (RCC).
As a result of participating in the activity, learners should be better able to:
Advances in the targeted therapy of metastatic RCC: Special emphasis on lenvatinib and cabozantinib
Immunotherapy with novel checkpoint inhibitors and targeted therapy combinations in the treatment of RCC
Conflict Of Interest Disclosure Policy
It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.
Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.
Hans Hammers, MD, PhD Associate Professor Kidney Cancer Program UT Southwestern Medical Center Dallas, TX
Dr. Hammers discloses that he is a consultant or has an advisory role with Bristol-Myers Squibb Co, Exelixis Inc., Pfizer Inc., Cerulean Pharma Inc., and Bayer AG; received research funding from SFJ Pharmaceuticals Inc., Bristol-Myers Squibb Co., Exelixis Inc., NewLink Genetic, Pfizer Inc., GlaxoSmithKline PLC, TRACON Pharmaceuticals Inc.; and is on the Speaker’s Bureau of Lilly USA, LLC, Eisai, Inc., Janssen, and Novartis.
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:
Hans Hammers, MD, PhD reported his disclosures under the Faculty heading above.
Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Scott & White Health and CancerNet. The A. Webb Roberts Center for CME of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.
The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.
The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Non-Endorsement of Products
The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.
There are no fees for participating and receiving CME credit for this webcast. During the period May 12, 2017 through May 12, 2018, participants must read all the material and study the educational webcast.
This webcast includes text, graphics, and may include multimedia features.
To obtain credit, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact the CME Provider at 214-820-2317.
Webb Roberts Center for CME of Baylor Scott & White Health observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.